What Does Science Say About Omega-3 Fatty Acids

What Does Science Say About Omega-3 Fatty Acids and Specific conditions ?

Minami Nutrition is about proof NOT promises. Our product range are produced as a result of our committment to research that examines the effect of Omega-3 fats on a variety of medical areas, including Dyslexia, Dyspraxia, Attention Deficit Hyperactivity Disorder (AD/HD) as well as Heart Disease and Wellness issues.

Clinical studies show that Omega-3 fatty acids are well tolerated by children and adults. The general consensus is that 1 g of EPA + DHA per day is sufficient to maintain optimum performance of the cardiovascular system in most people.*

Ongoing scientific research is revealing more about the enormous potential for Omega-3 fatty acids to positively impact on a range of health outcomes.*

Heart and Cardiovascular Disease*:
Prevention = 1 g EPA + DHA/day (1,2)
With high blood triglycerides = 2 to 4 g EPA + DHA/day (1)

Attention Deficit Hyperactivity Disorder (AD/HD), Dyslexia, Dyspraxia*:
0.5 to 1 g EPA/day (8)

Depression and Bipolar Disorder*:
1 to 2 g EPA/day as supplementary treatment with standard therapy (3-5)

Schizophrenia*:
2 g EPA/day as supplementary treatment with standard therapy (6)

Mood Disorder (aggression)*:
1 to 2 g EPA/day (7)

Pregnancy and Breast Feeding*:
220 to 800 mg EPA/day and 300 mg to 1 g DHA/day (9-11)

Brain and Visual Development*:
20-40 mg DHA/2.2 lb. body weight/day12

Preventive measures

- It is advisable not to take Omega-3 supplements if you are allergic to fish or gelatin
- It is advisable to tell your physician that you are taking Omega-3 supplements if you are about to have surgery or take anticoagulants

References

1. AHA: American Heart Association

2. ESC: European Society of Cardiology

3. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59(10):913-9.

4. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression : Report of a small open-label study. J Clin Psych 2005; 66(6):726-9.

5. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 2005 Feb 9;4(1):6.

6. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001 Apr 30;49(3):243-51.

7. Zanarini MC, Frankenburg FR. Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebocontrolled pilot study. Am J Psychiatry 2003; 160(1):167-9.

8. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2004; 70(4):383-90.

9. Simopoulos AP. The importance of the ratio of Omega-6/Omega-3 essential fatty acids. Biomed Pharmacother 2002; 56(8):365-79.

10. Facchinetti F, Fazzio M, Venturini P. Polyunsaturated fatty acids and risk of preterm delivery. Eur Rev Med Pharmacol Sci 2005; 9(1):41-8.

11. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics 2003; 111(1):e39-44.

12. WHO: World Health Organisation. Report of a joint expert FAO/WHO consultation, 1994.